NCT Number: NCT02665728
A Safety and Efficacy Evaluation of BLI400 Laxative in Constipated Adolescent Subjects
The objective of this study is to evaluate the safety and efficacy of BLI400 laxative in constipated adolescent subjects.
Looking for future studies?
Notify MeKey information
Conditions
Age range
12 year–17 year
Sex eligibility
All sexes
Study type
Interventional
Phase
Phase 2
Primary location
BLI Research Site 1, Miami, Florida, United States
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Male or female subjects at between 12-17 years of age
- Weight more than 40 kg (88 lbs.).
- Constipated, defined by the following criteria
- Fewer than 3 spontaneous defecations per week and at least one of the following symptoms for at least 12 weeks (which need not be consecutive) in the preceding 12 months:
- Straining during > 25% of defecations
- Lumpy or hard stools in > 25% of defecations
- Sensation of incomplete evacuation for > 25% of defecations
- Loose stools are rarely present without the use of laxatives
- There are insufficient criteria for irritable bowel syndrome - loose (mushy) or watery stool in the absence of laxative use for more than 25% of bowel movements
Criteria A, B and C must be fulfilled for the last 12 weeks with symptom onset at least 6 months prior to diagnosis.
- Otherwise in good health, as determined by physical exam and medical history
- If female, and of child-bearing potential, is using an acceptable form of birth control (hormonal birth control, intrauterine device, double-barrier method, depot contraceptive, sterilized, or abstinence)
- Negative urine pregnancy test at screening, if applicable
- In the Investigator's judgment, subject is mentally competent to provide informed consent to participate in the study
Exclusion criteria
- Subjects with known or suspected ileus, gastrointestinal obstruction, gastric retention, bowel perforation, toxic colitis, toxic megacolon
- Subjects who have had major surgery 30 days before Visit 1; appendectomy or cholecystectomy 60 days before Visit 1; abdominal, pelvic, or retroperitoneal surgery 6 months before Visit 1; bariatric surgery or surgery to remove a segment of the GI tract at any time before Visit 1
- Subjects with hypothyroidism that is being treated and for which the dose of thyroid hormone has not been stable for at least 6 weeks at the time of Visit 1
- Subjects taking laxatives, enemas or prokinetic agents that refuse to discontinue these treatments from Visit 1 until after completion of Visit 3
- Subjects who are pregnant or lactating, or intend to become pregnant during the study
- Subjects of childbearing potential who refuse a pregnancy test
- Subjects who are allergic to the study medication
- Subjects taking narcotic analgesics or other medications known to cause constipation
- Subjects who, in the opinion of the Investigator, should not be included in the study for any reason, including inability to follow study procedures
- Subjects who have participated in an investigational clinical, surgical, drug, or device study within the past 30 days
- Subjects with an active history of drug or alcohol abuse
- Subjects have been hospitalized for a psychiatric condition or have made a suicide attempt during the 2 years before Visit 1
- Subjects who withdraw consent at any time prior to completion of Visit 1 procedures
Treatment and study plan
Primary outcomes
-
Treatment Response
Time frame: 4 weeks
Overall treatment response is defined as weekly response in at least 2 out of 4 weeks. Weekly response is defined as greater than or equal to 3 spontaneous bowel movements during a week.
Sponsors and collaborators
Lead sponsor
Braintree Laboratories
Industry
Registry information
Important dates
- Study start
- 2015
- Primary completion
- 2016
- Study completion
- 2016
- First posted
- Jan 28, 2016
- Registry last updated
- Jun 26, 2020
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Development of a Constipation Risk Assessment Scale for Hospitalized Patients.
NCT04068415
Constipation, Pathological Conditions, Signs and Symptoms
View Trial DetailsMOWOOT Device Treatment for Adults With Chronic Constipation
NCT04666155
Constipation, Constipation - Functional
Durham, County Durham and Darlington, United Kingdom
View Trial DetailsDairy Products to Your Gut and Brain
NCT06311097
Constipation, Healthy
Copenhagen, Denmark
View Trial DetailsRadicle GI Health RDH™: A Study Assessing the Impact of Health and Wellness Products on Gastrointestinal (GI) Health and Related Health Outcomes
NCT07230821
Carbohydrate Metabolism, Inborn Errors, Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Del Mar, California, United States
View Trial Details